RKT Reckitt Benckiser Group plc
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under Vanish brand name; and disinfectant products under the Finish, Harpic, and Lysol brands. In addition, the company offers nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. Reckitt Benckiser Group plc was founded in 1819 and is headquartered in Slough, the United Kingdom.…
Industry Peers
Household & Personal ProductsKey Statistics
About Reckitt Benckiser Group (LON: RKT)
›
Reckitt Benckiser Group (LON: RKT) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Household & Personal Products industry, part of the Consumer Defensive sector, and reports about 36,200 employees.
The shares were at 5572.00 GBp on 19 November 2026, down 8.5% over 52 weeks. Its 52-week range is 3664.00 GBp to 6522.92 GBp: the price is 14.6% below the high and 52.1% above the low.
At a market capitalisation of 35.27B GBP, it trades at 12.5 times trailing earnings and 15.7 times forward earnings. The median trailing P/E of its 19 largest Household & Personal Products peers is 18.9, a discount of 33% for RKT. It pays a dividend yielding 3.79% (it pays out 49% of its earnings), against a median of 2.57% among the dividend payers in that peer group.
Reckitt Benckiser Group reports return on equity of 41.1%, an operating margin of 22.7% and revenue down 8.2% year over year.
Its debt exceeds its cash by 9.38B GBP, a debt-to-equity ratio of 1.09. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 6296.42 GBp is 13.0% above the current price. The next earnings report is expected on 25 February 2027.